SCHEMBL5543934

SCHEMBL5543934

O=C(Cl)N1CCN(c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.68
SMN1; SMN2 Q16637 7/20 0.68
HTT P42858 4/20 0.64
MAPK1 P28482 1/20 0.64
RAB9A P51151 1/20 0.61
USP2 O75604 1/20 0.59
ALOX15 P16050 1/20 0.59
HSD17B10 Q99714 1/20 0.59
ALDH1A1 P00352 3/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
GFER P55789 1/20 0.59
TP53 P04637 3/20 0.58
POLB P06746 1/20 0.58
LMNA P02545 3/20 0.57
ALOX12 P18054 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
TSHR P16473 1/20 0.57
RECQL P46063 1/20 0.57
PANK3 Q9H999 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27918171 0.88 MAPT (0.69) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL631834 0.86 MAPT (0.68) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL626652 0.85 HTR1A (0.67) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL18711281 0.85 MAPT (0.70) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL18375965 0.83 RAB9A (0.79) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL14452412 0.81 RAB9A (0.67) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL268788 0.81 RAB9A (0.67) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL18701803 0.81 MAPT (0.65) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL10144145 0.81 MAPT (1.00) MAPTSMN1; SMN2HTTMAPK1RAB9A
SCHEMBL1423584 0.80 AKR1C3 (0.67) MAPTSMN1; SMN2HTTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885SMN1; SMN2 3985/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.